Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Higham

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Pediatrics|March 14, 1998
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infectionB U Mueller, R P Nelson, J Sleasman, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
European Journal of Endocrinology|November 14, 2015
GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adultsD B Allen, P Backeljauw, M Bidlingmaier, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Systematic common and rare variant association testing in 392,030 whole genomes in <i>All of Us</i>Wenhan Lu, Robert J Carroll, Matthew Solomonson, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Pediatrics|March 14, 1998
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infectionB U Mueller, R P Nelson, J Sleasman, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
European Journal of Endocrinology|November 14, 2015
GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adultsD B Allen, P Backeljauw, M Bidlingmaier, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Systematic common and rare variant association testing in 392,030 whole genomes in <i>All of Us</i>Wenhan Lu, Robert J Carroll, Matthew Solomonson, et al.
Pageof 5